Shattuck Labs (STTK) Cash from Financing Activities (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Cash from Financing Activities of $25.8 million for Q1 2026, up 45368.42% year-over-year from N/an in Q1 2025, and up 19155.97% quarter-over-quarter from $134000.0 in Q4 2025.
Shattuck Labs (STTK) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Cash from Financing Activities for 8 consecutive years, with $25.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 45368.42% year-over-year to $25.8 million; the TTM figure through Mar 2026 stood at $70.4 million (up 7606.13% YoY), while the FY2025 annual figure was $44.6 million, up 5563.79% from the prior year.
- Cash from Financing Activities rose to $25.8 million in Q1 2026 per STTK's latest filing, from $134000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $48.6 million in Q4 2023 and bottomed at -$184000.0 in Q1 2024.
- Historically, Cash from Financing Activities has averaged $8.6 million across 5 years, with a median of $30000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 100.15% — and 2025, when it jumped 193365.22%.
- Shattuck Labs' Cash from Financing Activities stood at $27000.0 in 2022, then jumped by 179759.26% to $48.6 million in 2023, then tumbled by 100.15% to -$72000.0 in 2024, then surged by 286.11% to $134000.0 in 2025, then surged by 19155.97% to $25.8 million in 2026.
- Business Quant data shows STTK's Cash from Financing Activities at $25.8 million in Q1 2026, $134000.0 in Q4 2025, and $44.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | 128.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 128.01 Mn |
| Jun 30, 2026 | 128.01 Mn |
| Mar 31, 2026 | 25.80 Mn |
| Mar 31, 2026 | 25.80 Mn |
| Dec 31, 2025 | 134,000.00 |
| Dec 31, 2025 | 134,000.00 |
| Sep 30, 2025 | 44.50 Mn |
| Sep 30, 2025 | 44.50 Mn |
| Mar 31, 2025 | -57,000.00 |
| Mar 31, 2025 | -57,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | -184,000.00 |
| Mar 31, 2024 | -184,000.00 |
| Dec 31, 2023 | 48.56 Mn |
| Dec 31, 2023 | 48.56 Mn |